Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherCLINICAL INVESTIGATIONS

133Xe SPECT Cerebral Blood Flow Study in a Healthy Population: Determination of T-Scores

Daniel Olivier Slosman, Christian Chicherio, Catherine Ludwig, Laurence Genton, Sandrine de Ribaupierre, Didier Hans, Claude Pichard, Eugène Mayer, Jean-Marie Annoni and Anik de Ribaupierre
Journal of Nuclear Medicine June 2001, 42 (6) 864-870;
Daniel Olivier Slosman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Chicherio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Ludwig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence Genton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandrine de Ribaupierre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didier Hans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claude Pichard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eugène Mayer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marie Annoni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anik de Ribaupierre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Dementia is becoming a major health problem as the population of the Northern Hemisphere ages. Early differential diagnosis between normal cognitive decline and dementia is particularly difficult. If psychometric evaluation can contribute to the diagnosis, quantitative cerebral functional imaging would play an important role. We therefore proposed, first, to constitute a normative dataset that could later be used to identify subjects at risk for neurodegenerative processes and, second, to describe the risk of abnormal global cerebral blood flow (gCBF) by defining categories based on the standardized cutoff scores of a young, healthy population (T-score). Methods: Of a total of 203 healthy volunteers, 187 were included in the protocol, which included evaluation of medical history, neurologic and neuropsychologic status, and body composition; analysis of blood; and measurement of gCBF by means of 133Xe SPECT. Results: With ANOVA analysis using age and sex as between-subject factors and gCBF as a within-subject factor, a significantly higher gCBF was found in women than in men. In addition, a linear reduction as a function of age was observed for both sexes (−0.3%/y). T-score was determined for the 18- to 28-y-old age group, for whom gCBF was found to be 46.7 ± 5.1 mL/min/100 g tissue in men and 49.0 ± 5.0 mL/min/100 g tissue in women. The age-dependent decrease could thus be expressed in T-scores and, in the 29- to 38-y-old, 39- to 48-y-old, and >48-y-old age groups, averaged −0.63, −1.29, and −1.92, respectively, in men and −0.63, −0.83, and−2.40, respectively, in women. Cognitive performance, body composition, and blood analysis revealed the expected significant effects from sex and age. Conclusion: The large-scale reference database of gCBF measurements constituted from a healthy, well-controlled population enabled age and sex stratification, which showed significant differences between the sexes and a significant decline as a function of age. T-scores were determined and warrant further studies on the prospective identification of early dementia by 133Xe SPECT in elderly individuals.

  • cerebral perfusion
  • SPECT
  • 133Xe
  • T-score
  • healthy population

Dementia affects approximately 5% of the population aged 65 y old or older (1,2). From a recent prospective study with a 5-y follow-up, the annual incidence of dementia was determined to be 1.3%, and the incidence varied with age and sex from 0.23% per year in all men to 6.6% per year in women aged 90 y old or older (3). Alzheimer’s disease (AD) is considered the most common cause of dementia in older people and exacts a substantial cost from society (4).

Normal cognitive decline with aging has been recognized and includes slowing of processing speed and impairment of some aspects of executive functioning, especially working memory (1). These age-related effects need to be differentiated from the cognitive decline present in AD. A neuropsychologic evaluation can contribute to this differential diagnosis during the course of the disease, but optimal management requires an early diagnosis and assessment of dementia. Brain imaging techniques may play a critical role in such an assessment. Numerous authors agree that a high correlation exists between clinically diagnosed AD and reduced cerebral blood flow (CBF) or cerebral glucose metabolism. Recently, Crawford (5) even suggested that reduced CBF may be a required cofactor in the development of AD.

We hypothesized that quantitative assessment of CBF may be valuable for screening individuals for potential degenerative processes. Therefore, we proposed to constitute a normative dataset that could later be used to identify individuals at risk for neurodegenerative processes. We also proposed to describe the risk of abnormal CBF by defining categories based on standardized cutoff scores. For this purpose, we used the T-score, an extension of the z score, which is the most commonly used standardized index in life sciences and expresses each individual’s score relative to the mean and SD of a matched population. In this study, a large-scale reference database of global CBF (gCBF) measurements was constituted from a healthy, well-controlled population stratified by age and sex. On that basis, gCBF standardized values were computed. Furthermore, the assessment of the reference healthy population was optimized by evaluating the cognitive performance of all subjects by means of neuropsychologic testing.

MATERIALS AND METHODS

Subjects

Through advertisement, 203 healthy volunteers were recruited from the Geneva University Hospital and from the local recreational scuba-diving community. All volunteers were informed of the research content and the approval of the ethical committee (Department of Clinical Neurosciences, Geneva University Hospital, Geneva, Switzerland) and gave written informed consent to participate. The protocol included evaluation of medical history, neurologic and neuropsychologic status, body composition (using dual x-ray absorptiometry, bioimpedance, and 40K anthropogammametry analysis (6)); analysis of blood (glucose, high-density lipoprotein [HDL], low-density lipoprotein [LDL], cholesterol, and triglycerides); and measurement of gCBF. Only the 187 volunteers who met the following defined criteria were included in the study: no diagnosis of depression or dementia; no psychiatric disease, neurologic disease, blindness, diabetes, hypertension, vascular disease, arteriosclerosis, or history of decompression illness; no current use of antipsychotic, antidepressant, anticonvulsant, antiparkinsonian, or antidiabetic drugs; and no current use of narcotics, methyldopa, clonidine, acetazolamide (Diamox; Lederle, Zug, Switzerland), Codergocrini Mesilas (Hydergine; Novarta Pharma, Basel, Switzerland), or cognition-enhancing medication.

Neuropsychologic Evaluation

Neuropsychologic testing was performed to gather information on cognitive functioning. The tests assessed the speed and flexibility of information processing, perceptual-motor abilities, spatial discrimination, and memory. The Trail-Making test (TMT) (7) requires speed, visual scanning, and the ability to sequentially connect numeric symbols in a simple task (part A) or more complex alphanumeric symbols in a task that requires flexibility (part B). The time to complete part A (TMTA) and part B (TMTB) was considered in this test. An adaptation of the Thurstone test (8) was used to evaluate spatial discrimination and speed of information processing. Performance is assessed in terms of the number of correct responses (BG9). Two subtests of the Attention Evaluation Battery (9) were selected; the former measures speed of analysis and flexibility processes (F) and the latter evaluates working memory abilities (MT). In both subtests, performance is assessed in terms of both median response time (F_MED and MT_MED) and number of correct items (F_COR and MT_COR). The inclusion condition of the Process Dissociation procedure (S. Adam and M. Van Der Linden, written communication, 2000) was used to evaluate recall from memory and was expressed as number of items correctly recalled (NINC). Finally, the Mill Hill multiple-choice vocabulary scale (10) was used as a measure of semantic knowledge, which was assessed in terms of the number of items correctly discriminated (MHB).

Imaging Technique

Inhaled-133Xe SPECT was used to measure brain perfusion (11–13). The gas 133Xe was obtained from a commercial source (DuPont Pharma, Winterthur, Switzerland/Heider AG, Winterthur, Switzerland) and was administered to the volunteers using a dispenser system (XAS SM32C; Ceretronix, Randers, Denmark). SPECT was performed using a triple-head CGA-9300 camera (Toshiba, Tokyo, Japan) and dedicated protocols that enabled the simultaneous determination of CBF in all brain regions in a single 10-min acquisition. Parallel-hole, low-energy, superhigh-sensitivity collimation dedicated to xenon dynamic SPECT acquisition was used. The volunteers were in the dorsal decubitus position, with eyes closed and ears plugged, in a quiet room with low ambient light. After 2 min of training to familiarize the volunteers with the inhalation system, they were asked to rest and breath quietly for 11 min. During the first minute, imaging was simultaneous with inhalation of 740 MBq (20 mCi) 133Xe. After diffusion, the remaining 10 min of imaging were dedicated to tracer elimination (washout period). Data were acquired with 360° of rotation, step-and-shoot mode (step angle, 6°; rotation time, 30 s), a 64 × 64 matrix, and a zoom of ×1.5. Images were reconstructed with a prefiltering Butterworth (order 8, with 0.15 cutoff Nyquist frequency) and a ramp filter but without attenuation correction, as recommended by Toshiba. Clearance curves were used to determine the regional CBF in mL/min/100 g of cerebral tissue using the calculation method of Kanno and Lassen (14). Then, the early-picture protocol (Toshiba), consisting of observation of a single picture integrated over the first 2-min interval, was applied. This method was sufficiently reproducible and provided a coefficient of variation of 6.3% (15). Contiguous images were reconstructed in the sagittal, coronal, and transaxial planes from the orbitomeatal line with a slice thickness of 1 pixel (8.5 mm). The voxel size was 8.53 mm. CBF measurements were expressed in terms of gCBF. Representative images are shown in Figure 1.

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

133Xe SPECT images of healthy volunteer. Results are presented as successive transaxial planes from top to bottom. Brain volume is included in 12 consecutive planes. First plane shows planar orientation (right [R], left [L], anterior [A], and posterior [P]). Last plane shows brain volume of analysis. Pixel values of regional CBF are color coded and express quantitative measurement in mL/min/100 g tissue equivalent.

Statistical Analysis

The reference sample was defined as volunteers 18–28 y old and will be referred to as the young healthy adult (YHA) sample. The remainder of the population was divided into 3 age groups: 29–38 y old, 39–48 y old, and >48 y old.

Using this YHA reference sample, the T-score of each individual was computed as follows: Math where T-sc gCBF is the T-score of a given individual; observed gCBF value is the measure of gCBF for the given individual; mean gCBF YHA is the mean gCBF value of the reference sample (YHA); and SD gCBF YHA is the SD measured in the reference sample (YHA).

Age was chosen as the criterion for grouping the volunteers so that the sensitivity of the T-score in identifying age-related changes could be determined. Body mass index was defined as weight/(height2). Statistical analysis was performed with STATISTICA (StatSoft, Inc., Tulsa, OK) for Windows 2000 (Microsoft, Redmond, WA).

For the overall cohort and for the YHA group, 2-way ANOVA with age (18–28 y old, 29–38 y old, and 39–48 y old) and sex as between-subject factors was first performed on gCBF measurements. The >48-y-old group was not included in those analyses because it contained too few women. Regression analysis was used to assess the relationship between age and gCBF for each sex. Two-way ANOVA with a 3 × 2 design was then performed separately for cognitive performance, anthropometric measurements, and laboratory findings.

RESULTS

Functional Brain Imaging

ANOVA analysis using age and sex as between-subject factors and gCBF as a within-subject factor found that age (F2,161 = 12.34, P < 0.001) and sex (F1,161 = 12.69, P < 0.001) had a significant effect. Namely, women showed a higher gCBF (45.6 ± 5.9 mL/min/100 g) than did men (42.2 ± 5.0 mL/min/100 g), and those values were significantly reduced with advancing age. No age × sex interaction was found. Moreover, as displayed in Figure 2, a significant linear reduction as a function of age was observed for both sexes (for men, R2 = 0.222, P < 0.001; for women, R2 = 0.238, P < 0.001). When age groups were considered, the age-dependent decrease in gCBF remained (Table 1) and could be expressed in T-scores. In the 29- to 38-y-old, 39- to 48-y-old, and >48-y-old age groups, the T-scores averaged −0.63, −1.29, and −1.92, respectively, in men and −0.63, −0.83, and−2.40, respectively, in women.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Linear regression of gCBF as function of age for men (M) and women (F), separately.

View this table:
  • View inline
  • View popup
TABLE 1

Determination of gCBF Measurements per Group of Age and Sex

The box plot of sex-adjusted T-scores in Figure 3 shows the regular decline in gCBF as a function of age and enabled us to hypothesize that with a cutoff value of −3.5 for the T-score, we would obtain a relative frequency of 4.5% for abnormality in the >48-y-old group (containing individuals from 50 to 71 y old). This frequency corresponds to the prevalence of dementia in the general population. Nevertheless, when the YHA group was considered, sex or age had no significant effect on gCBF.

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Box plot graph of T-score (T-SC) adjusted for sex as function of age.

Cognitive Performance

ANOVA using age and sex as between-subject factors and cognitive performance as a within-subject factor found significant effects mainly from age and more selectively from sex. In other words, older subjects were slower in their reaction times on MT_MED (F2,161 = 3.9, P < 0.05), F_MED (F2,161 = 8.2, P < 0.001), TMTA (F2,161 = 6.7, P < 0.005), and TMTB (F2,161 = 3.44, P < 0.05). Nevertheless, older subjects performed less accurately on MT_COR (F2,161 = 6.9, P < 0.005) but not on F_COR. Both significant main effects of age and sex were identified on BG9 (for age, F2,161 = 6.6, P < 0.005; for sex, F1,161 = 5.8, P < 0.05), which showed reduced performance both for men and for older groups. One interaction was found with main effects of age and sex on NINC (F2,158 = 4.4, P < 0.05), which showed decreased scores for men with advancing age. No significant effects were found on educational level and semantic knowledge (MHB), suggesting that the observed differences could not be explained by confounding effects of education and vocabulary. Mean values and SDs for cognitive performance are presented in Table 2.

View this table:
  • View inline
  • View popup
TABLE 2

Cognitive Performance of Cohort Included in Age × Sex ANOVA

Physical Characteristics and Laboratory Findings

Mean values and SDs are presented in Tables 3 (physical characteristics) and 4 (laboratory findings). ANOVA using age and sex as between-subject factors and physical characteristics as a within-subject factor found the effects of sex on weight (F1,160 = 101.5, P < 0.001), height (F1,160 = 104.1, P < 0.001), and body mass index (F1,160 = 25.5, P < 0.001) to be significant. Significant main effects of both age and sex were observed on lean mass (for age, F2,158 = 3.1, P < 0.05; for sex, F1,158 = 334.7, P < 0.001) and percentage of fat (for age, F2,158 = 3.2, P < 0.05; for sex, F1,158 = 64.6, P < 0.001). No significant effects were found on fat mass. In contrast, ANOVA performed on laboratory findings showed significant main effects of age on glucose (F2,158 = 5.2, P < 0.01), cholesterol (F2,158 = 8.3, P < 0.001), and LDL (F2,158 = 9.1, P < 0.001). A significant main effect of sex was observed on HDL (F1,158 = 62.8, P < 0.001). No significant effects on triglycerides were found. Table 5 presents the overall data for the YHA group used to define the T-score. These values are unremarkable or within reference ranges. Furthermore, body composition and, in particular, percentage of body fat mass had no significant impact on gCBF when adjusted for age.

View this table:
  • View inline
  • View popup
TABLE 3

Physical Characteristics of Cohort Included in Age × Sex ANOVA

View this table:
  • View inline
  • View popup
TABLE 4

Laboratory Findings of Cohort Included in Age × Sex ANOVA

View this table:
  • View inline
  • View popup
TABLE 5

Cognitive Performance, Physical Characteristics, and Laboratory Findings of YHA Cohort

DISCUSSION

SPECT functional brain imaging is now recognized as a powerful clinical and research tool because of its modern instrumentation enabling, in particular, quantitative measurement of CBF with 133Xe (13). The importance of our study rests on the careful and extensive screening of a large sample to define a healthy population for each sex, the determination of T-scores for each sex as a possible clinical parameter to assess neurodegenerative diseases, and the comparison of neuropsychologic performances using an extensive battery of tests.

For more than 20 y, many studies have been performed to assess variations in CBF, the cerebral metabolic rate of glucose (CMRglu), or oxygen use with age. Unfortunately, although an age-related decline has been documented by some authors (16–30), others have found no such decline (30–36). Suboptimal technology that could not measure global brain activity may partially explain the negative results noted in the publications of the late 1970s and early 1980s. In more recent studies that did not show a decline in gCBF or CMRglu with age, the mode of subject selection, the pooling of sex in the analysis, and the limited number of subjects should be underlined. Kushner et al. (33) investigated 13 young and 17 elderly (aged 47–73 y) healthy volunteers with FDG PET. Tempel and Perlmutter (35) measured gCBF with H215O in 26 subjects aged 20–72 y. Similarly, Swartz et al. (36) observed in their cohort of 32 women and 15 men not only no age-related decline in gCBF as measured by 133Xe SPECT but also no difference between the sexes. On the contrary, Yoshii et al. (26) found, with 18F-FDG PET, that global CMRglu declined as a function of age and was higher in women than in men. The percentage of difference between the sexes in young adults was 0.8%, which compares favorably with the 1% observed in our YHA population, considering that the authors defined young adults as individuals < 50 y old. With 133Xe SPECT, Devous et al. (25) not only observed an age-related decline in CBF but also showed that CBF was higher in women of all ages. For the assessment of CBF, 133Xe was chosen because it remains the most accurate way to perform quantitative measurements with SPECT, it does not require blood sampling, it does not rely on intermediate biologic processes (37,38), and it is not associated with non–flow-dependent focal retention (39), as are the technetium-labeled compounds ethylcysteinate dimer or hexamethylpropyleneamine oxime. The contradictory observations and negative results of these studies may also stem from a small sample size and a wide age range. Because of our large population, our results strongly support an age-related decline in gCBF and a sex-related difference in gCBF, as suggested previously.

Age-related and sex differences have been studied for many years in the psychologic literature. Although effects related to age are well documented, less consistent results have been obtained for the identification of sex differences. Speed of processing, executive functioning, and some aspects of memory are well known to be reduced in aging. Sex differences are often discussed in the literature in terms of better processing of verbal information in women and visuospatial information in men. We therefore expected age and sex to affect those variables. In our study, expected age reductions were observed for variables measuring effortful recall from memory (NINC) and working memory (MT_MED, MT_COR), speed of processing (TMTA, BG9), and flexibility (TMTB, F_MED), which could be identified as a crucial component in executive functioning. Sex differences were more controversial. Better performance for women was found in speed of processing but also in recall from memory with advancing age (NINC). The fact that the latter test requires processing of verbal information could explain the observed advantage. In contradiction to the expected results, no clear information could be identified in disfavor of women, particularly in visuospatial processing.

In one study, CBF and CMRglu were observed to increase as children grew older, with a peak in activity at approximately the age of 6–9 y (40). Then, after a slight decline that might not be statistically significant because of the small sample, the peak was followed by a plateau in young adults and then by a regular decline with aging. We hypothesized that neurodegenerative diseases could be screened using a normative dataset, with cutoffs defined in terms of standardized cutoff scores to a reference group. The relationship between a low CBF or CMRglu value and the presence of dementia has already been established, but there is still no defined classification for the subject investigated. The determination of a T-score for gCBF measurement may therefore become important for further investigating the ability of CBF to assess the risk of dementia. The T-score represents a young adult z score and is expressed as SDs dependent on a specified value for a parameter as measured for a young adult healthy reference group. The advantage of the T-score is that it is independent of measurement units and can be used across different instruments if their reference parameters are derived from the same group of healthy volunteers. Thus, further studies are needed for 2 reasons: first, to determine regional CBF T-scores in the YHA population so that the relationship between psychometric performances and rCBF can be studied and, second, to validate gCBF as a screening criterion for the early diagnosis of dementia.

CONCLUSION

The large-scale reference database of gCBF measurements constituted from a healthy, well-controlled population enabled an age and sex stratification that showed a significant difference between the sexes and a significant decline as a function of age. T-scores were determined and warrant further studies on the prospective identification of early dementia by 133Xe SPECT in elderly individuals.

Acknowledgments

The authors thank Mohamed Allaoua, Luc Terraneo, Yannick Sermet, and Christina Laemmli for their contribution to data collection, image processing, and clinical interpretation. This study was supported by the Gustave Prevot Foundation.

Footnotes

  • Received Oct. 28, 2000; revision accepted Feb. 15, 2001.

    For correspondence or reprints contact: Daniel Olivier Slosman, MD, Division of Nuclear Medicine, Geneva University Hospital, 1211 Geneva 14 Switzerland.

REFERENCES

  1. ↵
    Keefover RW. Aging and cognition. Neurol Clin 1998;16:635–648.
    OpenUrlCrossRefPubMed
  2. ↵
    Fratiglioni L, DeRonchi D, Agüero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging 1999;15:365–375.
    OpenUrlCrossRefPubMed
  3. ↵
    Letenneur L, Gillereon V, Commenges D, et al. Are sex and educational level independent predictors of dementia and Alzheimer’s disease? Incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry 1999;66:177–183.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997;278:1363–1371.
    OpenUrlCrossRefPubMed
  5. ↵
    Crawford JG. Alzheimer’s disease risk factors as related to cerebral blood flow: additional evidence. Med Hypotheses 1998;50:25–36.
    OpenUrlCrossRefPubMed
  6. ↵
    Slosman DO, Casez J-P, Pichard C, et al. Assessment of whole-body composition using dual-energy x-ray absorptiometry. Radiology 1992;185:593–598.
    OpenUrlPubMed
  7. ↵
    Davies ADM. The influence of age on trail making test performance. J Clin Psychol 1968;24:96–98.
    OpenUrlPubMed
  8. ↵
    Bonnardel R, Examen B. Batterie Factorielle Standard. Issy les Moulineaux, France: Editions Scientifiques et Psychologiques; 1977.
  9. ↵
    Zimmerman P, Fimm B. Test d’évaluation de l’attention (TEA), adaptation française par P. North, M. Leclerq, N. Crémel, P. Tassi, D. Heromin. Würselen, Germany: Psychologische Testsysteme; 1994.
  10. ↵
    Raven JC. Revised Manual for Raven’s Progressive Matrices and Vocabulary Scale. Windsor, U.K.: NFER Nelson; 1982.
  11. ↵
    Stirling Meyer J, Ishihara N, Deshmukh VD, et al. Improved method for noninvasive measurement of regional cerebral blood flow by xenon-133 inhalation. Stroke 1978;9:195–205.
    OpenUrlAbstract/FREE Full Text
  12. Lassen NA, Henriksen L, Paulson O. Regional cerebral blood flow in stroke by 133xenon inhalation and emission tomography. Stroke 1981;12:284–288.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Devous MD. SPECT functional brain imaging. J Neuroimaging 1995;5.(suppl):S2–S13.
  14. ↵
    Kanno I, Lassen NA. Two methods for calculating regional cerebral blood flow from emission computed tomography of inert gas concentrations. J Comput Assist Tomogr 1979;3:71–76.
    OpenUrlPubMed
  15. ↵
    Slosman DO, Chicherio C, Genton L, et al. Study of the reproducibility of cerebral blood flow (CBF) measurement using quantitative xenon-133 SPECT [abstract]. Eur J Nucl Med 1999;26:1135.
    OpenUrl
  16. ↵
    Naritomi H, Meyer JS, Sakai F, et al. Effects of advancing age on regional cerebral blood flow: studies in normal subjects with risk factors for atherothrombotic stroke. Arch Neurol 1979;36:410–416.
    OpenUrlCrossRefPubMed
  17. Frackowiack RSJ, Lenzi G-L, Jones T, et al. Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man using 15O and positron emission tomography: theory, procedure, and normal values. J Comput Assist Tomogr 1980;4:727–736.
    OpenUrlCrossRefPubMed
  18. Melamed E, Lavy S, Bentin S, et al. Reduction in regional cerebral blood flow during normal aging in man. Stroke 1980;11:31–35.
    OpenUrlAbstract/FREE Full Text
  19. Kuhl DE, Metter EJ, Riege WH, et al. Effects of human aging on patterns of local cerebral glucose utilization determined by the (F-18)fluorodeoxyglucose method. J Cereb Blood Flow Metab 1982;2:163–171.
    OpenUrlPubMed
  20. Davis SM, Ackerman RH, Correia JA, et al. Cerebral blood flow and cerebrovascular CO2 reactivity in stroke-age normal controls. Neurology 1983;33:391–399.
    OpenUrlAbstract/FREE Full Text
  21. Yamaguchi T, Hatazawa J, Kubota K, et al. Correlation between regional cerebral blood flow and age-related atrophy: a quantitative study with computed tomography and the xenon-133 inhalation method. J Am Geriatr Soc 1983;31:412–416.
    OpenUrlPubMed
  22. Pantano P, Baron J-C, Lebrun-Grandié P, et al. Regional cerebral blood flow and oxygen consumption in human aging. Stroke 1984;15:635–641.
    OpenUrlAbstract/FREE Full Text
  23. Shaw TG, Mortel KF, Meyer JS, et al. Cerebral blood flow changes in benign aging and cerebrovascular disease. Neurology 1984;34:855–862.
    OpenUrlAbstract/FREE Full Text
  24. Shirahata N, Henriksen L, Vorstrup S, et al. Regional cerebral blood flow assessed by Xe-133 inhalation and emission tomography: normal values. J Comput Assist Tomogr 1985;9:861–866.
    OpenUrlPubMed
  25. ↵
    Devous MD, Stokely EM, Chehabi HH, et al. Normal distribution of regional cerebral blood flow measured by dynamic single-photon emission tomography. J Cereb Blood Flow Metab 1986;6:95–104.
    OpenUrlPubMed
  26. ↵
    Yoshii F, Barker WW, Chang JY, et al. Sensitivity of cerebral glucose metabolism to age, gender, brain volume, brain atrophy, and cerebrovascular risk factors. J Cereb Blood Flow Metab 1988;8:654–661.
    OpenUrlPubMed
  27. Leenders KL, Perani D, Lammertsma AA, et al. Cerebral blood flow, blood volume and oxygen utilization: normal values and effect of age. Brain 1990;113:27–47.
    OpenUrlAbstract/FREE Full Text
  28. Martin AJ, Friston KJ, Colebatch JG, et al. Decreases in cerebral blood flow with normal aging. J Cereb Blood Flow Metab 1991;11:684–689.
    OpenUrlPubMed
  29. Waldemar G, Hasselbalch SG, Andersen AR, et al. 99mTc-d,l-HMPAO and SPECT of the brain in normal aging. J Cereb Blood Flow Metab 1991;11:508–521.
    OpenUrlPubMed
  30. ↵
    Takada H, Nagata K, Hirata Y, et al. Age-related decline of cerebral oxygen metabolism in normal population detected with positron emission tomography. Neurol Res 1992;14.(2 suppl):128–131.
  31. de Leon MJ, Ferris SH, George AE, et al. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer’s disease. J Cereb Blood Flow Metab 1983;3:391–394.
    OpenUrlPubMed
  32. Dastur DK. Cerebral blood flow and metabolism in normal human aging, pathological aging, and senile dementia. J Cereb Blood Flow Metab 1985;5:1–9.
    OpenUrlPubMed
  33. ↵
    Kushner M, Tobin M, Alavi A, et al. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET. J Nucl Med 1987;28:1667–1670.
    OpenUrlAbstract/FREE Full Text
  34. Itoh M, Hatazawa J, Miyazawa H, et al. Stability of cerebral blood flow and oxygen metabolism during normal aging. Gerontology 1990;36:43–48.
    OpenUrlPubMed
  35. ↵
    Tempel LW, Perlmutter JS. Vibration-induced regional cerebral blood flow responses in normal aging. J Cereb Blood Flow Metab 1992;12:554–561.
    OpenUrlPubMed
  36. ↵
    Swartz JR, Lesser IM, Boone KB, et al. Cerebral blood flow changes in normal aging: SPECT measurement. Int J Geriatr Psychiatry 1995;10:437–446.
    OpenUrlCrossRef
  37. ↵
    Jacquier-Sarlin MR, Polla BS, Slosman DO. Oxido-reductive state: the major determinant for cellular retention of HMPAO-Tc99m. J Nucl Med 1996;37:1694–1697.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Jacquier-Sarlin M, Slosman DO, Polla A. The cellular basis of ECD brain retention. J Nucl Med 1996;37:1694–1697.
  39. ↵
    Papazyan J-P, Delavelle J, Burkhard P, et al. Discrepancies between HMPAO and ECD SPECT imaging in brain tumor. J Nucl Med 1997;38:592–596.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol 1987;22:487–497.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 42 (6)
Journal of Nuclear Medicine
Vol. 42, Issue 6
June 1, 2001
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
133Xe SPECT Cerebral Blood Flow Study in a Healthy Population: Determination of T-Scores
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
133Xe SPECT Cerebral Blood Flow Study in a Healthy Population: Determination of T-Scores
Daniel Olivier Slosman, Christian Chicherio, Catherine Ludwig, Laurence Genton, Sandrine de Ribaupierre, Didier Hans, Claude Pichard, Eugène Mayer, Jean-Marie Annoni, Anik de Ribaupierre
Journal of Nuclear Medicine Jun 2001, 42 (6) 864-870;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
133Xe SPECT Cerebral Blood Flow Study in a Healthy Population: Determination of T-Scores
Daniel Olivier Slosman, Christian Chicherio, Catherine Ludwig, Laurence Genton, Sandrine de Ribaupierre, Didier Hans, Claude Pichard, Eugène Mayer, Jean-Marie Annoni, Anik de Ribaupierre
Journal of Nuclear Medicine Jun 2001, 42 (6) 864-870;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Accuracy of Parenchymal Cerebral Blood Flow Measurements Using Pseudocontinuous Arterial Spin-Labeling in Healthy Volunteers
  • Brain-Derived Neurotrophic Factor Val66Met Polymorphism Affects Resting Regional Cerebral Blood Flow and Functional Connectivity Differentially in Women Versus Men
  • Negative neurofunctional effects of frequency, depth and environment in recreational scuba diving: the Geneva "memory dive" study
  • Google Scholar

More in this TOC Section

  • Diagnostic Performance of 124I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma
  • Effects of Tracer Uptake Time in Non–Small Cell Lung Cancer 18F-FDG PET Radiomics
  • A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition
Show more CLINICAL INVESTIGATIONS

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire